The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.
In early reports on 125I-VIP binding experiments in liver membranes, it has been proposed that, the VIP binding sites were partially sensitive to GTP. Here we confirm that the VIP binding sites of chicken liver membranes consisted mainly in bivalent VIP/PACAP receptors and that about 50% of the 125I-VIP binding capacity was not affected by the GTP analogue GppNHp. Part of these bivalent receptors also appeared to represent PHI binding sites. In GppNHp-treated membranes, the GTP-insensitive VIP binding sites displayed a 17-fold higher relative affinity than in control membranes for the VIP analogue PHI. Such data suggested that GTP-insensitive VIP receptors may correspond to a subclass of high-affinity PHI receptors. Cross-linking of 125 I-VIP or 125 I-PHI to their receptors, revealed 2 components of 48 and 60 kDa. The radiolabelling of the 60 kDa component was strongly affected by increasing concentrations of the GTP analogue but was modestly abolished by an excess of PHI. Conversely, the radiolabelling of the 48 kDa molecular form was not affected by the GTP analogue but was efficiently abolished by increasing concentrations of PHI. Taken together, the data suggest that the 48 kDa component expressed in chicken liver membranes display the properties of a GTP-insensitive VIP/PHI receptor that can be pharmacologically discriminated from the GTP-sensitive 60 kDa form, through its much higher affinity for PHI.
Pineau
N
N
Groupe de Biologie des Interactions Cellulaires, LBSC, CNRS UMR6558, Université de POITIERS, France.
Lelievre
V
V
Goursaud
S
S
Hilairet
S
S
Waschek
J A
JA
Janet
T
T
Muller
J M
JM
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002645:Chickens; D003432:Cross-Linking Reagents / Q000378:metabolism / Q000494:pharmacology; D006160:Guanosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism*; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D007457:Iodine Radioisotopes; D008099:Liver / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism / Q000494:pharmacology; D010451:Peptide PHI / Q000378:metabolism / Q000494:pharmacology*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011869:Radioligand Assay; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D011979:Receptors, Pituitary Hormone / Q000378:metabolism; D018005:Receptors, Vasoactive Intestinal Peptide / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000494:pharmacology
D003432:Cross-Linking Reagents; D007457:Iodine Radioisotopes; D009479:Neuropeptides; D010451:Peptide PHI; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D011979:Receptors, Pituitary Hormone; D018005:Receptors, Vasoactive Intestinal Peptide; D006165:Guanylyl Imidodiphosphate; D014660:Vasoactive Intestinal Peptide; D006160:Guanosine Triphosphate